Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

06-06-2021 | ASCO 2021 | Conference coverage | Video

VISION trial supports LuPSMA-targeting therapy for mCRPC

Michael Morris discusses the VISION trial findings demonstrating a survival benefit with LuPSMA-targeted therapy for men with heavily pretreated metastatic castration-resistant prostate cancer (7:44).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

15-02-2019 | Castration-resistant prostate cancer | News

Further support for [177Lu]-PSMA-617 in men with mCRPC

11-02-2021 | ASCO GU 2021 | Conference coverage | Video

Updated TheraP data further support LuPSMA for mCRPC
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits